Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 89c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $254.28 +2.24%
Financial Fact:
Intangible asset amortization: 26.45M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Intangible asset amortization: 26.45M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.20, $0.89 better than the analyst estimate of $3.31. Revenue for the quarter came in at $838.1 million versus the consensus estimate of $832.52 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Is the global equity rally broadening? UBS weighs in
- Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
